Qualigen Therapeutics, Inc. (QLGN)
Automate Your Wheel Strategy on QLGN
With Tiblio's Option Bot, you can configure your own wheel strategy including QLGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol QLGN
- Rev/Share 0.0
- Book/Share 22.7569
- PB 0.0835
- Debt/Equity 0.0
- CurrentRatio 1.0111
- ROIC -8.0631
- MktCap 3107412.0
- FreeCF/Share -4899.2521
- PFCF -0.4356
- PE -0.0004
- Debt/Assets 0.0
- DivYield 0
- ROE 7.4167
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Published: July 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 …
Read More
About Qualigen Therapeutics, Inc. (QLGN)
- IPO Date 2015-06-23
- Website https://qlgntx.com
- Industry Biotechnology
- CEO Kevin A. Richardson II
- Employees 4